RxDoctor Payments Data

Caleb Kil

Medical · la Palma, CANPI 1699319848

Payments from drug & device makers

$6,390in general payments, 2019–2025

Across 353 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$845
  • Novo Nordisk$732
  • AbbVie$639
  • Novartis$548
  • AstraZeneca$470
  • Lilly USA, LLC$387
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$6,29599%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,390 in reported general payments places this provider in the 90th percentile of 2,087 medical providers in California.

See all medical providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin44$46,663
OzempicSemaglutide39$40,593
RybelsusSemaglutide15$29,432
MounjaroTirzepatide19$19,107
ProliaDenosumab11$18,423
TrulicityDulaglutide13$13,988
EntrestoSacubitril/Valsartan13$11,169
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,532
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,593
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen73$1,401
Atorvastatin Calcium102$1,258
Pregabalin15$1,121
Levocetirizine Dihydrochloride43$808
Valsartan30$801
Celecoxib36$750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$732$70,02554 claims
Boehringer IngelheimJardiance$206$46,66344 claims
Lilly USA, LLCMounjaro, Trulicity$387$33,09632 claims
AmgenProlia$845$18,42311 claims
NovartisEntresto$548$11,16913 claims
GSKTrelegy Ellipta$127$10,53217 claims
AstraZenecaBreztri Aerosphere$470$9,59313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 medical providers in California.

Other medical in la Palma

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →